2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…2016 American Transplant Congress
Limiting Helper Functions of CD4 T Cells Improves Efficacy of Induction Therapy without Compromising Responses to Third Party Antigens.
Antibody mediated lymphocyte depletion is commonly used in clinical transplantation. However, memory T cells undermine the efficacy of lymphoablative induction therapies in sensitized transplant recipients.…2016 American Transplant Congress
Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.
Introduction: There are limited data assessing the appropriate weight to use when dosing Thymoglobulin for induction therapy. The aim of this study is to assess…2016 American Transplant Congress
Earlier Repletion of Lymphocytes After Alemtuzumab Induction Is Associated with a Lower Incidence of Infection Following Renal Transplantation.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Alemtuzumab has been increasingly used as an induction agent in renal transplantation, although the optimal dose is unknown. We have previously reported that alemtuzumab…2016 American Transplant Congress
Role of Induction Therapy in Low Immune Risk Kidney Transplant Recipients.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy improves outcomes in kidney transplant recipients (KTRs) by reducing early acute rejection. In the current era of potent maintenance immunosuppression, the role of…2016 American Transplant Congress
Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.
Background: Clinical trials of induction agents typically exclude older recipients, so our practice in older recipients is extrapolated from this. Older adults are different, so…2016 American Transplant Congress
Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) vs Basiliximab After Kidney Transplantation: A Health Economic Analysis from a German Perspective.
Study objective. A health economic analysis was undertaken to quantify the economic consequences of acute rejection and serious adverse events in patients receiving induction with…2016 American Transplant Congress
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.
Efficacy of CNI- and corticosteroid-free immunosuppressive regimens has not been demonstrated in large, multicenter trials. BEST (Belatacept-based Early Steroid Withdrawal Trial) (NCT 01729494) compares 2…2016 American Transplant Congress
Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation.
Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic.
Mononuclear phagocytes and neutrophils play a key role in early responses against the transplanted kidney allograft. It is expected that during the reperfusion of kidney…2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 31
- Next Page »